Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 mai 2026 16h48 HE | Source: Knight Therapeutics

Knight Therapeutics Inc. announces voting results from the Annual General Meeting

MONTREAL, May 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) pharmaceutical company, announced today the voting results from...
06 mai 2026 13h30 HE | Source: Custom Market Insights

Global RNA Targeting Small Molecule Drug Discovery Market Size/Share Worth USD 17.6 Billion by 2035 at a 22.1% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)

Austin, TX, USA, May 06, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “RNA Targeting Small Molecule Drug Discovery Market Size, Trends and Insights By...
04 mai 2026 13h04 HE | Source: Eascra Biotech

Eascra Biotech Welcomes Dr. Anne Yau as Life Science Research Scientist

Nanomedicine expert joins Massachusetts Biomedical Initiatives (MBI) lab in Worcester to advance RNA therapeutics for musculoskeletal disease
30 avr. 2026 07h30 HE | Source: Knight Therapeutics

Notice of Knight Therapeutics' First Quarter 2026 Results Conference Call

MONTREAL, April 30, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) pharmaceutical company, will release its first quarter 2026 financial results on...
27 avr. 2026 16h30 HE | Source: Custom Market Insights

Global Compression Garments and Stockings Market Size/Share Worth USD 5.10 Billion by 2035 at a 4.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

Austin, TX, USA, April 28, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Compression Garments and Stockings Market Size, Trends and Insights By Product...
24 avr. 2026 16h00 HE | Source: Compass Therapeutics

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer

Webcast scheduled for Monday, April 27, 2026 at 8:00am ET. BOSTON, April 24, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical...
15 avr. 2026 07h30 HE | Source: Knight Therapeutics

Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference

MONTREAL, April 15, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-US) specialty pharmaceutical company, announced today that Samira Sakhia, President...
31 mars 2026 07h01 HE | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Announces 2025 Annual Results

60 Degrees Pharma (Nasdaq: SXTP) FY25 revenue +65% to $1.0M; improved net loss; continued clinical, commercial, and partnership momentum.
27 mars 2026 12h26 HE | Source: Knight Therapeutics

Knight Therapeutics Inc. ranks on The Globe and Mail’s second annual Canada’s Top Growing Women-Led Companies and seventh annual Women Lead Here benchmark of executive gender diversity

MONTREAL, March 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it has been recognized on two of The Globe and Mail’s Report on...
25 mars 2026 11h11 HE | Source: Faruqi & Faruqi LLP

NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options If you purchased or...

Page suivante